Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding

Cirrhosis Clinical Trial

— EXARHOSE  

Official title:

Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03023189
• Other study ID #: P150959
• Secondary ID: 2016-002677-35
• Status: Recruiting
• Phase: Phase 4
• First received: December 23, 2016
• Last updated: April 10, 2018
• Start date: April 3, 2017
• Est. completion date: April 2020

Study information

• Verified date: April 2018
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Matthieu HEIDET, MD
• Email: matthieu.heidet[@]aphp.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Upper digestive bleeding. Upper gastrointestinal haemorrhage is a common cause of decompensated cirrhosis and is associated with a high mortality rate among cirrhotic patients. Its leading cause is the rupture of gastro-esophageal varices due to portal hypertension. In cirrhotic patients, the management of acute gastrointestinal haemorrhage is challenging as they often present with coagulation (or haemostasis abnormalities) abnormalities such as hyperfibrinolysis, especially when the cirrhosis is decompensated. Beyond life support measures, therapeutic modalities of upper gastrointestinal bleeding rely on both endoscopic and pharmacological interventions. Tranexamic acid (TA) is an antifibrinolytic that may help control the bleeding in this setting, as it showed an unquestionable benefit in other indications. TA has previously been studied in both upper gastrointestinal haemorrhage from any causes and in liver transplantation of cirrhotic patients. However, there is a lack of data to conclude on its effectiveness (or efficiency) in the early treatment of acute bleeding in cirrhotic patients.

Investigators hypothesize that, when given early, TA would be beneficial for cirrhotic patients presenting with acute upper gastrointestinal haemorrhage , by controlling the haemorrhage, avoiding rebleeding episodes and reducing mortality within 5 days after its administration. Moreover, TA could prevent early cirrhosis complications (such as hepatic encephalopathy, sepsis and ascites liquid infection, hepatorenal syndrome), could reduce indications to transjugular portosystemic shunt (TIPS), shorten the length of stay in intensive care unit and the length of hospitalization, and decrease late relapses and one-year mortality.

Description:

Acute Upper gastrointestinal haemorrhage (UGIH) is frequent, with an estimated annual incidence of 150/100 000 in France. Its second etiology is the rupture of portal hypertension-related gastro-esophageal varices, accounting for 20 % of the patients and responsible for more than 50 % of the hospitalizations in intensive care unit (ICU) for UGIH.

In cirrhotic patients, variceal bleeding is the main cause of UGIH (over 70 %) and death (30 %), which occurs in the most severe patients (Child-Pugh score B or C and/or high MELD score, and high levels of portal hypertension).

Acute UGIH is directly responsible for 50 % of the deaths, either because it remains uncontrolled during the acute phase (within 5 days), or because of early relapses (within 6 weeks). Every episode of acute UGIH worsens the middle and long-term vital prognosis: about 60 % of the patients present with UGIH recurrence within one year and the survival rate is only 30 % 3 years after the first episode.

Moreover, acute UGIH is a triggering factor for several severe cirrhosis-specific complications (such as hepatic encephalopathy, sepsis and ascites liquid infection, hepatorenal syndrome), which themselves lead to high mortality rates. Despite the improvement of preventive, diagnostic and therapeutic strategies, UGIH remains stable in France.

The haemostasis of cirrhotic patients is often abnormal at baseline : thrombopenia, decrease of factors II, V, VII, IX, X and XI, decrease of fibrinolytic proteins, increase of factor VIII and spontaneous fibrinolysis. When compensated, the cirrhotic's haemostasis remains globally preserved, due to the balance of pro and anticoagulant alterations.

Every cause of cirrhosis decompensation, such as acute PHT-UGIH, can increase hemostatic disorders, leading to hyperfibrinolysis. This could slow down or inhibit the clotting, thus disrupting pharmacological control of acute UGIH.

TA could be efficient in acute UGIH of cirrhotic patients. It is a simple antifibrinolytic which showed clinical benefits on haemorrhage and/or mortality in several other indications (surgical, obstetrical and traumatic). It is now widely used according to recommendations.

Early administration of TA seems to be beneficial in UGIH haemorrhage. Despite theoretical efficiency, 4 recent Cochrane meta-analysis concluded to the lack of significant data (poor overall trials quality). The benefit of the use of TA in acute UGIH (and acute PHT-UGIH) remains uncertain.

At this day, TA has still not been studied in acute UGIH of cirrhotic patients, although it showed benefits on blood transfusion's requirements and on haemorrhagic complications during liver transplantation (for which cirrhosis most frequent cause).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: April 2020
• Est. primary completion date: April 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria (modified by amendment1)

• Age = 18

• Patient treated by a prehospital physician-staffed SMUR team, a firefighter physician-staffed ambulance (ARBSPP), an hospital EMS or an ICU

• Acute upper digestive bleeding (< 24h) in the shape of hematemesis, described either by the physician, the patient, a relative or a member of the medical team

• Known or suspected cirrhosis (based on clinical/biological/radiographic/anamnestic data)

• Affiliated or recipient of the French social security

• Written consent (or under emergency procedures)

Exclusion Criteria (modified by amendment1)

• Known ongoing pregnancy or breastfeeding

• TA already given (if inter-hospital transfer)

• Endoscopy already performed for the current haemorrhagic episode

• Hospitalization for over 24h in an intensive care unit or a routine care unit

• Exclusive lower digestive bleeding or melena only

• Patient in cardiac arrest at the arrival of the prehospital medical team, whether recovered or not

• Patient already randomised once in EXARHOSE study

• TA Counter-indications

• creatininemia > 500 µmol/L or documented clearance < 30 mL/min

• documented ongoing CIVD (prior to UDB)

• ongoing seizures

• ongoing arterial or venous thrombosis

• allergy

• Known participation of the patient to another therapeutic study

• Known linguistic inability of the patient to understand the study

• Patient under known guardianship

Related Conditions & MeSH terms

• Cirrhosis
• Fibrosis
• Gastrointestinal Hemorrhage
• Hemorrhage
• Upper Digestive Bleeding

Intervention

Drug:
• Tranexamic acid
At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h. Total dose : 4 g of TA
• Placebo
At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo

Locations

Country	Name	City	State
France	Jean Verdier Hospital	Bondy
France	Henri Mondor Hospital	Creteil
France	Marc Jacquet Hospital	Melun

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The main outcome is a composite criterion and includes: control on acute bleeding, absence of re-bleeding episodes at day 5 and absence of death at day 5 (modified by amendment 1)	Specifically, the composite criterion is defined by all the following criteria: Immediate control of the hemorrhage after initial patient management using splanchnic vasoconstrictors and/or proton pump inhibitors, potentially including volume expander, transfusion and/or prescription of vasopressor amines : Achievement of the transfusion target (Hb = 7 g/dL) 24 hours after initial patient management and then until day 5; Absence of initiation or increase in vasopressor amines, until day 5; Absence of recourse to the transfusion of 2 or more red cells packs within 24h to maintain the transfusion target (Hb = 7 g/dL); Absence of persistence or evolution towards haemorrhagic shock (systolic blood pressure < 100 mmHg and/or mean arterial pressure < 60 mmHg and/or heart rate > 100 bpm); Absence of re-bleeding episodes at day 5, assessed by the medical team on the bases of clinical, biological or endoscopic elements; Absence of death at day 5	5 days after randomisation
Secondary	Control of the bleeding	At least 1 criterion present : Persistence of the bleeding (regardless of the volume), 2 hours after initiation of medical or endoscopic treatment; And/Or blood transfusion needed within 24 hours after treatment initiation (= 2 red cells units); And/Or hemorrhagic shock installation (systolic blood pressure < 100 mmHg and/or mean arterial pressure < 60 mmHg and/or heart rate > 100 bpm)	Within 5 days after randomisation
Secondary	Re-bleeding episodes		At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
Secondary	Death		At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
Secondary	Fluid infusion volume (in mL)		At day 6, day 28 and day 42 after randomisation
Secondary	Blood transfusion volume (in mL)		At day 6, day 28 and day 42 after randomisation
Secondary	Blood transfusion quantity (number of units)		At day 6, day 28 and day 42 after randomisation
Secondary	Nature of blood transfusion: - Red cells units - Platelets units - Fresh frozen plasma - Fibrinogen - Other		At day 6, day 28 and day 42, after randomisation
Secondary	TIPS procedure (in Child-Pugh B patients)		At day 6, day 28, day 42 after randomisation
Secondary	Visceral and systemic complications	Complications, defined as: Acute organ failure (using CLIF-C ACLF and CLIF-SOFA scores); Hepatic encephalopathy; Hepatic failure; Hepatorenal syndrome; Renal failure (using grades 2 and 3 of the KDIGO classification); Sepsis; Ascites liquid infection	At day 6, day 28 and day 42, after randomisation (or until discharge)
Secondary	Need for organ substitution - Renal replacement therapy (dialysis) - Liver replacement therapy - Mechanical ventilation		At day 6, day 28 and day 42, after randomisation (or until discharge)
Secondary	Liver transplantation		At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
Secondary	Length of stay in ICU (in days)		At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
Secondary	Duration of hospitalization (in days)		At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation
Secondary	Number of participants with treatment-related adverse events as assessed by the ANSM notice of Exacyl®	Adverse events as assessed by the ANSM notice of Exacyl® are : Allergy; Thrombotic events; Seizures; Acute renal failure (KDIGO grades 2 and 3); Death; Or any other adverse event suspected to be treatment-related; Adverse effects will be systematically searched for and collected in the electronic Case Report Form (eCRF) during the acute phase (within 5 days after randomization), as assessed by the AP-HP notification form. When present, investigators will have to send a notification to the promoter (by fax). Patients with severe adverse effects (leading to death, life-threatening condition, hospitalization and pursuit of hospitalization, incapacity or handicap, congenital malformation) will be followed until disappearance of these. Every document related to the patient during the protocol should be transmitted to the promoter. Investigators are supposed to answer every inquiry of the promoter.	up to 5 days
Secondary	Delay between the beginning of the haemorrhage and the initiation of the AT treatment		At day 1